← Leaderboards
William T Comer
Neurogenetic Pharmaceuticals, Inc.
$4,731,841
Attributed
$6,106,360
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–17$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,106,360 · 2
By mechanism
U44$3,357,322 · 1
R01$2,749,038 · 1
Top collaborators
- Maria Zoe Kounnas4 shared
Most similar at Neurogenetic Pharmaceuticals, Inc.
Same institution · by research overlap
- Maria Zoe Kounnas$1,374,519
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsNeurogeneticsInnovationInhibitor/AntagonistMemory LossNerve DegenerationElderlyDementiaGamma SecretaseImpaired CognitionAffectAmericanAmyloid Beta-ProteinMultienzyme ComplexesAlzheimer&AposConfusionAdverse EffectsCostAlzheimer Disease PreventionElementsBaseCellular DevelopmentBehavioralNotch Protein
Grant awards (9)
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$136,920
R01 · FY2017 · AG
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$1,093,421
R01 · FY2016 · AG
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$138,884
R01 · FY2016 · AG
Phase 1 clinical studies with the gamma-secretase modulator, NGP 555 to establish safety, pharmacokinetics, and biomarker efficacy$1,379,813
R01 · FY2015 · AG
Pre-clinical development of NGP 555 for the prevention of AD$999,249
U44 · FY2014 · NS · contact PI
Pre-clinical development of NGP 555 for the prevention of AD$70,000
U44 · FY2014 · NS · contact PI
Pre-clinical development of NGP 555 for the prevention of AD$999,911
U44 · FY2013 · NS · contact PI
Pre-clinical development of NGP 555 for the prevention of AD$999,681
U44 · FY2012 · NS · contact PI
Pre-clinical development of NGP 555 for the prevention of AD$288,481
U44 · FY2011 · NS · contact PI